ArticleTranslational cancer research2026
Prognostic modeling and validation of middle ear malignancy outcomes on the basis of SEER population data.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant neoplasms of the middle ear represent a rare yet aggressive entity, with limited evidence regarding prognostic determinants and therapeutic outcomes. This study aimed to evaluate the association between radiotherapy (RT) and survival outcomes, and to develop a prognostic nomogram for middle ear malignancies using the Surveillance, Epidemiology, and End Results (SEER) database. Methods: A retrospective cohort analysis was performed on 206 patients diagnosed with middle ear malignancies from the SEER database [1975-2021]. Demographic and clinical variables, including age, sex, race, tumor stage, surgical intervention, RT, and chemotherapy, were analyzed. Survival outcomes were assessed using the Kaplan-Meier (K-M) method and multivariate Cox proportional hazards (PH) regression models. A nomogram predicting 1-, 3-, and 5-year overall survival (OS) was constructed and internally validated. Results: RT was administered to 56% of patients (n=112) and was associated with a 72% increased risk of mortality compared to patients not receiving RT [hazard ratio (HR) =1.72, 95% confidence interval (CI): 1.16-2.55; P=0.007]. Patients aged ≥65 years exhibited a 2.6-fold higher mortality risk (HR =2.61; 95% CI: 1.75-3.88; P<0.001). Compared with localized disease, unknown tumor stage was linked to a 75% lower mortality risk (HR =0.25; 95% CI: 0.09-0.71; P=0.009), likely reflecting data limitations rather than a true protective effect. Advanced tumor stage significantly impacted OS (P=0.007). The nomogram incorporating age, race, laterality, tumor stage, surgical intervention, chemotherapy, and RT demonstrated good discriminative ability, with area under the curve (AUC) values of 0.707, 0.740, and 0.752 for 1-, 3-, and 5-year OS prediction, respectively. Conclusions: An association between RT and increased mortality risk was observed in patients with middle ear malignancies; however, this finding should be interpreted cautiously due to potential confounding and treatment selection bias inherent in retrospective database analyses. Age and tumor stage were identified as important prognostic factors. The developed nomogram offers a practical tool for individualized survival prediction to aid clinical decision-making. Prospective studies are needed to validate these findings and clarify the role of RT in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.